Rash News and Research

RSS

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

Positive preliminary results from Alnylam's Phase I ALN-PCS trial on severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the achievement of positive preliminary results from its ongoing clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia.

5 Jan 2012

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

The NSW Health authorities are warning residents and visitors in southern and western NSW to take extra precautions and protect themselves against mosquitoes following the detection of the Murray Valley Encephalitis (or MVE) virus in NSW. Residents and visitors to North Victoria are also similarly warned.

1 Jan 2012

FDA approves Merck's Isentress to treat HIV-1 infection in children, adolescents

Isentress (raltegravir) was approved today by the U.S. Food and Drug Administration for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents ages 2-18.

22 Dec 2011

Fluoride supplements not found to be safe or effective

According to the Cochrane Oral Health Group, fluoride supplements fail to reduce tooth decay in primary teeth, permanent teeth cavity-reduction is dubious and health risks are little studied.

19 Dec 2011

New gel could nip Lyme borreliosis infection in the bud

They come out in the spring, and each year they spread further - the ticks. Thirty percent of them transmit borrelia pathogens, the causative agent of Lyme borreliosis that can damage joints and organs.

19 Dec 2011

Lab results change in consistent ways during the course of Kawasaki disease

Children with Kawasaki disease show a pattern of changing laboratory test results as the disease runs its course, according to a study in the December issue of The Pediatric Infectious Disease Journal.

15 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Tips for parents to protect children from holiday dangers

The holidays are an exciting and busy time of year as parents race to finish the shopping, decorating and baking. As the number of days left in the calendar year winds down, be sure to allow plenty of time in that hectic schedule for playing with your child and sharing holiday traditions as a family. Nationwide Children's Hospital reminds parents to keep alert to various holiday dangers.

12 Dec 2011

Breast cancer hope with new drug and new combination regimens

last week at the San Antonio Breast Cancer Symposium, researchers announced encouraging results from studies of two cancer medications that appeared to keep breast cancer from advancing.

11 Dec 2011

FDA approves changes to REMS for Nplate and Promacta

The approval of changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag) was announced by the U.S. Food and Drug Administration.

7 Dec 2011

Measles raises its head again in Europe after years of suppression: Report

According to a new report last Thursday, measles incidence is on the rise in Europe following decades of decline. Up to October European health officials reported more than 26,000 measles cases this year and nine deaths.

5 Dec 2011

University of Illinois Hospital prescribes Tumor Treating Fields therapy for recurrent GBM

The University of Illinois Hospital is the first center in North America to prescribe a new FDA-approved treatment for patients with the most common and aggressive type of brain tumor, glioblastoma multiforme, or GBM.

3 Dec 2011

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

Shots reduce risk of chicken pox

Infants below the age of one may be too young to get the chicken pox vaccine but far fewer of them got the itchy rash after the U.S. started routinely vaccinating older children in 1995, according to a new study.

29 Nov 2011

NHS Choices launches new penis health gallery for men

Could you spot genital warts from herpes, or crabs from a rash? Now you can. NHS Choices, the health information website for the NHS, has launched a new penis health gallery to help men spot common problems with their penises.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Genzyme's alemtuzumab Phase lll trial on MS meets co-primary endpoints

Genzyme, a Sanofi company, reports today that the Phase lll CARE-MS ll trial met both of its co-primary endpoints. Relapse rate and sustained accumulation (worsening) of disability (SAD) were significantly reduced in multiple sclerosis patients receiving alemtuzumab as compared with Rebif.

14 Nov 2011

Long-range wind transport of an infectious agent may cause KD

Kawasaki Disease (KD) is a severe childhood disease that many parents, even some doctors, mistake for an inconsequential viral infection. In fact, if not diagnosed or treated in time, it can lead to irreversible heart damage. After 50 years of research, including genetic studies, scientists have been unable to pinpoint the cause of the disease.

10 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011